

---

## FUTURE PLANS AND [REDACTED]

---

### FUTURE PLANS

For details of our future plans, see “Business—Our Strategies.”

#### [REDACTED]

We estimate that we will receive [REDACTED] of approximately HK\$[REDACTED] after deducting the [REDACTED] and expenses payable by us in the [REDACTED] assuming an [REDACTED] of HK\$[REDACTED] per [REDACTED], being the mid-point of the indicative [REDACTED] range of HK\$[REDACTED] to HK\$[REDACTED] per [REDACTED] set out in this document. We intend to use the [REDACTED] from the [REDACTED] for the following purposes:

- (i) approximately [REDACTED]%, or HK\$[REDACTED], will be allocated for the development and registration of our Core Product, QX002N, of which:
  - (a) approximately [REDACTED]%, or HK\$[REDACTED], will be allocated to fund the Phase III clinical trials (including costs for trial sites, CROs and subject enrollment) of QX002N in China for the treatment of AS. We commenced a Phase III clinical trial in China in September 2023 to evaluate safety and efficacy of QX002N in adult patients with active AS. We expect to complete such trial in the second half of 2025;
  - (b) approximately [REDACTED]%, or HK\$[REDACTED], will be allocated for the CMC costs and the preparation of requisite registration filings of QX002N;
- (ii) approximately [REDACTED]%, or HK\$[REDACTED], will be allocated for the development and registration of our other Core Product, QX005N, of which:
  - (a) approximately [REDACTED]%, or HK\$[REDACTED], will be allocated to fund the clinical trials (including costs for trial sites, CROs and subject enrollment) of QX005N in China for the treatment of AD in adults. We commenced a Phase II clinical trial for AD in adults in China in September 2022 to evaluate the efficacy, safety, PK and PD profile of QX005N in adult patients with moderate-to-severe AD. We expect to complete such trial in the first quarter of 2024. As of the Latest Practicable Date, we had applied to consult with the NPMA for the commencement of the Phase III clinical trial;
    - (1) approximately [REDACTED]%, or HK\$[REDACTED], will be allocated to the Phase II clinical trial; and
    - (2) approximately [REDACTED]%, or HK\$[REDACTED], will be allocated to the Phase III clinical trial;

---

## FUTURE PLANS AND [REDACTED]

---

- (b) approximately [REDACTED]%, or HK\$[REDACTED], will be allocated to fund the clinical trials (including costs for trial sites, CROs and subject enrollment) of QX005N in China for the treatment of PN. We commenced a Phase II clinical trial for PN in China in February 2023 to evaluate the efficacy, safety, PK and PD profile of QX005N in adult patients with PN. We expect to complete the Phase II clinical trial in the first quarter of 2024. As of the Latest Practicable Date, we had applied to consult with the NMPA for the commencement of the Phase III clinical trial;
- (1) approximately [REDACTED]%, or HK\$[REDACTED], will be allocated to the Phase II clinical trial; and
- (2) approximately [REDACTED]%, or HK\$[REDACTED], will be allocated to the Phase III clinical trial;
- (c) approximately [REDACTED]%, or HK\$[REDACTED], will be allocated for the Phase II clinical trials (including costs for trial sites, CROs and subject enrollment) of QX005N in China for the treatment of CRSwNP. We commenced a Phase II clinical trial of QX005N in China for the treatment of CRSwNP in April 2023 to evaluate the safety, efficacy, PK and PD of QX005N in adult patients with CRSwNP and plan to complete such trial in the fourth quarter of 2024; and
- (d) approximately [REDACTED]%, or HK\$[REDACTED], will be allocated for the CMC costs and the preparation of requisite registration filings of QX005N;
- (iii) approximately [REDACTED]%, or HK\$[REDACTED], will be allocated for the development and registration of QX004N, including costs for trial sites, CROs and subject enrollment for the Phase Ib and Phase II clinical trials of QX004N for the treatment of Ps and the Phase Ib and Phase II clinical trials of QX004N for the treatment of CD, and CMC costs of QX004N. We commenced a Phase Ib clinical trial in China in February 2023 to evaluate the safety, tolerability, efficacy and PK profile of QX004N in adult patients with moderate-to-severe plaque Ps. We expect to complete such trial in the second quarter of 2024. We also commenced a Phase II clinical trial in China in September 2023 to evaluate the efficacy, safety and PK and PD profile of QX004N in adult patients with moderate-to-severe plaque Ps. We expect to complete such trial in the first half of 2025. We also plan to initiate a Phase Ib clinical trial in China depending the data from the Phase Ia clinical trial for CD to evaluate the safety, efficacy, PK and tolerability of multiple intravenous injections of QX004N in adult patients with CD.
- (iv) approximately [REDACTED]%, or HK\$[REDACTED], will be allocated for clinical development of QX006N, including the clinical trials (including costs for trial sites, CROs and subject enrollment), preparation of registration filings and CMC costs of QX006N; and
- (v) approximately [REDACTED]%, or HK\$[REDACTED], will be allocated for the research and development of certain of our other assets, including QX007N, QX010N and QX013N, and drug discovery.

---

## FUTURE PLANS AND [REDACTED]

---

The above allocation of the [REDACTED] will be adjusted on a *pro rata* basis in the event that the [REDACTED] is fixed at a higher or lower level compared to the mid-point of the indicative [REDACTED] range. If the [REDACTED] is set at HK\$[REDACTED] per Share, being the high end of the indicative [REDACTED] range, the [REDACTED] from the [REDACTED] will increase by approximately HK\$[REDACTED]. If the [REDACTED] is set at HK\$[REDACTED] per Share, being the low end of the indicative [REDACTED] range, the [REDACTED] from the [REDACTED] will decrease by approximately HK\$[REDACTED].

If the [REDACTED] are not immediately applied to the above purposes, we will only deposit those [REDACTED] into short-term interest-bearing accounts at licensed commercial banks and/or other authorized financial institutions (as defined under the Securities and Futures Ordinance, and the relevant applicable laws in the relevant jurisdiction for non-Hong Kong based deposits). We will make an appropriate announcement if there is any change to the above proposed [REDACTED].